We use cookies to ensure that the website works as intended and to collect statistics on its use so that we can improve your web site experience.

×

Aker BioMarine’s Patent Portfolio is Strengthened in the United States

(August 31, 2022) The United States Patent Trial and Appeal Board (PTAB) has rejected a challenge against Aker BioMarine’s...

Breakthrough study demonstrates positive effects of krill oil to improve osteoarthritis of the knee

Oslo, July, 27, 2022: A new study conducted by CSIRO, Australia’s national science agency, across three clinical trial sites...

Aker BioMarine - second quarter 2022

14 July 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 73 million and Adjusted EBITDA...

Aker BioMarine Supports Antarctic Ecosystem Research with USD 1 Million

(June 30th, 2022, Oslo) At the UN Ocean Conference in Lisbon this week, Aker BioMarine announced its commitment to support...

Ocean 14 Capital invests in AION

Ocean 14 Capital Ltd., a private equity firm that invests in companies and technologies offering sustainable solutions for...

Aker BioMarine secures FDA approval for QRILL Aqua in the United States

The US salmon farming industry can now benefit from the proven health and nutritional benefits of krill. As of June 10th,...

QRILL Aqua strengthens team with two new executive hires

Oslo, May 25, 2022: Aker BioMarine is adding to its Animal Health and Nutrition Business Unit organizational chart after...